<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027777</url>
  </required_header>
  <id_info>
    <org_study_id>OBPM_Ambulatory2019</org_study_id>
    <nct_id>NCT04027777</nct_id>
  </id_info>
  <brief_title>Aktiia OPBM Single-center Prospective Observational Study Against Double Auscultation</brief_title>
  <official_title>Single-center Prospective Observational Study to Validate the Performance of the Aktiia Optical Blood Pressure Monitoring (OBPM) Device at the Wrist Against Double Auscultation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aktiia SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aktiia SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre prospective observational study to validate the performance of the Aktiia SA&#xD;
      optical blood pressure monitoring (OBPM) device at the wrist against blood pressure&#xD;
      measurements obtained by double auscultation at the upper arm during four weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the World Health Organization, by 2025 hypertension will affect 1.5 billion&#xD;
      adults worldwide. Half of the adult population is not diagnosed, and half of the treated&#xD;
      population is not at the defined target of BP. Widespread use of out of office BP measurement&#xD;
      is one of the proposed strategies to fight against hypertension worldwide.&#xD;
&#xD;
      The current Ambulatory Blood Pressure Monitoring or Home Blood Pressure Monitoring are&#xD;
      performed with a cuff placed around the arm. This 110-year-old technology is not only&#xD;
      uncomfortable for the patient but can also result in a number of overestimated readings due&#xD;
      to the stress induced while inflating the cuff.&#xD;
&#xD;
      Aktiia S.A. has developed an intermittent automated non-invasive cuffless blood pressure&#xD;
      monitor determining over a series of cardiac cycles the values of the systolic blood&#xD;
      pressure, the diastolic blood pressure and the heart rate. This miniature device is&#xD;
      comfortably positioned with a bracelet on a user's wrist. The optical sensors integrated&#xD;
      within the device exploit the principle of reflection photoplethysmography (PPG) to capture&#xD;
      the user's skin pulsatility (change of arterial diameter occurring at each heartbeat). Aktiia&#xD;
      OBPM algorithms are further applied to the recorded PPG signal to determine user's blood&#xD;
      pressure and heart rate.&#xD;
&#xD;
      Because the measurement relies on optical sensors, and not on pneumatic cuffs, Aktiia OBPM&#xD;
      device provides an increased overall comfort to the patient throughout the monitoring, does&#xD;
      not induce sleep arousal during the night measurements and decreases the false positive&#xD;
      readings induced by the stress associated with the cuff inflation. Aktiia OBPM device is&#xD;
      intended to be used in the long term, as compared to one-day or one-week use of Ambulatory&#xD;
      Blood Pressure Monitors.&#xD;
&#xD;
      This study over several visits has been designed to assess both the accuracy and the&#xD;
      stability of the Aktiia OBPM. The automaticity of the measurement when performed in different&#xD;
      body positions and upon aerobic exercise was also evaluated.&#xD;
&#xD;
      By demonstrating both the accuracy and the stability of the measurements that can be&#xD;
      performed in different body positions with a comfortable and miniature Aktiia OBPM device,&#xD;
      Aktiia SA aims to make one step further in facilitating blood pressure measurement and&#xD;
      monitoring in the out-of-clinic scenarios and integrating blood pressure monitoring into&#xD;
      user's daily life. The diagnosis and treatment of hypertension in ambulatory settings is&#xD;
      expected to largely benefit from these advancements&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure absolute Mean Error</measure>
    <time_frame>Up to four weeks</time_frame>
    <description>The absolute value of the mean of the differences between Reference and Aktiia.product-P0 blood pressure determinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure standard Deviation of the Error</measure>
    <time_frame>Up to four weeks</time_frame>
    <description>The standard deviation of the differences between Reference and Aktiia.product-P0 determinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate root-mean-square error</measure>
    <time_frame>Up to four weeks</time_frame>
    <description>The root-mean-square difference between the Aktiia.product-P0 heart rate determinations and the Reference method</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Aktiia.product-P0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main study arm including 85 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aktiia.product-P0 Diabetics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second study arm including 40 diabetic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aktiia.product-P0 Aged</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirs study arm including 40 patients aged 65+</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aktiia.product-P0</intervention_name>
    <description>The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.</description>
    <arm_group_label>Aktiia.product-P0</arm_group_label>
    <arm_group_label>Aktiia.product-P0 Aged</arm_group_label>
    <arm_group_label>Aktiia.product-P0 Diabetics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ARM1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects (aged between 21 and 65 years old)&#xD;
&#xD;
          -  Subjects fluent in written and spoken French&#xD;
&#xD;
          -  Subjects agreeing to attend the totality of 4 visits&#xD;
&#xD;
          -  Subjects that have signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with tachycardia (heart rate at rest &gt; 120bpm)&#xD;
&#xD;
          -  Subjects with atrial fibrillation&#xD;
&#xD;
          -  Subjects with diabetes&#xD;
&#xD;
          -  Subjects with renal dysfunctions (eGFR &lt; 60mL/min/1.73 m2)&#xD;
&#xD;
          -  Subjects with hyper-/hypothyroidism&#xD;
&#xD;
          -  Subjects with pheochromocytoma&#xD;
&#xD;
          -  Subjects with Raynaud's disease&#xD;
&#xD;
          -  Subjects with trembling and shivering&#xD;
&#xD;
          -  Subjects with interarm systolic difference &gt; 15 mmHg&#xD;
&#xD;
          -  Subjects with interarm diastolic difference &gt; 10 mmHg&#xD;
&#xD;
          -  Subjects with arm paralysis&#xD;
&#xD;
          -  Women in known pregnancy&#xD;
&#xD;
          -  Subjects with an arteriovenous fistula&#xD;
&#xD;
          -  Subjects with arm amputations&#xD;
&#xD;
          -  Subjects with the upper arm circumference &gt; 64 cm&#xD;
&#xD;
          -  Subjects with the wrist circumference &gt; 22 cm (limitation due Aktiia.bracelet-P0 size)&#xD;
&#xD;
          -  Subjects with the central phalanx of the middle finger circumference &gt; 71 mm or &lt; 43&#xD;
             mm&#xD;
&#xD;
          -  Subjects with the exfoliative skin diseases (limitation due to participant discomfort)&#xD;
&#xD;
          -  Subjects with lymphoedema (limitation due to participant discomfort)&#xD;
&#xD;
        ARM2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects (aged between 21 and 65 years old)&#xD;
&#xD;
          -  Subjects fluent in written and spoken French&#xD;
&#xD;
          -  Subjects agreeing to attend the totality of 4 visits&#xD;
&#xD;
          -  Subjects that have signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with tachycardia (heart rate at rest &gt; 120bpm)&#xD;
&#xD;
          -  Subjects with atrial fibrillation&#xD;
&#xD;
          -  Subjects with hyper-/hypothyroidism&#xD;
&#xD;
          -  Subjects with pheochromocytoma&#xD;
&#xD;
          -  Subjects with Raynaud's disease&#xD;
&#xD;
          -  Subjects with trembling and shivering&#xD;
&#xD;
          -  Subjects with interarm systolic difference &gt; 15 mmHg&#xD;
&#xD;
          -  Subjects with interarm diastolic difference &gt; 10 mmHg&#xD;
&#xD;
          -  Subjects with arm paralysis&#xD;
&#xD;
          -  Women in known pregnancy&#xD;
&#xD;
          -  Subjects with an arteriovenous fistula&#xD;
&#xD;
          -  Subjects with arm amputations&#xD;
&#xD;
          -  Subjects with the upper arm circumference &gt; 64 cm&#xD;
&#xD;
          -  Subjects with the wrist circumference &gt; 22 cm (limitation due Aktiia.bracelet-P0 size)&#xD;
&#xD;
          -  Subjects with the central phalanx of the middle finger circumference &gt; 71 mm or &lt; 43&#xD;
             mm&#xD;
&#xD;
          -  Subjects with the exfoliative skin diseases (limitation due to participant discomfort)&#xD;
&#xD;
          -  Subjects with lymphoedema (limitation due to participant discomfort)&#xD;
&#xD;
        ARM3&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects (aged between 65 and 85 years old)&#xD;
&#xD;
          -  Subjects fluent in written and spoken French&#xD;
&#xD;
          -  Subjects agreeing to attend the totality of 4 visits&#xD;
&#xD;
          -  Subjects that have signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with tachycardia (heart rate at rest &gt; 120bpm)&#xD;
&#xD;
          -  Subjects with atrial fibrillation&#xD;
&#xD;
          -  Subjects with diabetes&#xD;
&#xD;
          -  Subjects with renal dysfunctions (eGFR &lt; 60mL/min/1.73 m2)&#xD;
&#xD;
          -  Subjects with hyper-/hypothyroidism&#xD;
&#xD;
          -  Subjects with pheochromocytoma&#xD;
&#xD;
          -  Subjects with Raynaud's disease&#xD;
&#xD;
          -  Subjects with trembling and shivering&#xD;
&#xD;
          -  Subjects with interarm systolic difference &gt; 15 mmHg&#xD;
&#xD;
          -  Subjects with interarm diastolic difference &gt; 10 mmHg&#xD;
&#xD;
          -  Subjects with arm paralysis&#xD;
&#xD;
          -  Women in known pregnancy&#xD;
&#xD;
          -  Subjects with an arteriovenous fistula&#xD;
&#xD;
          -  Subjects with arm amputations&#xD;
&#xD;
          -  Subjects with the upper arm circumference &gt; 64 cm&#xD;
&#xD;
          -  Subjects with the wrist circumference &gt; 22 cm (limitation due Aktiia.bracelet-P0 size)&#xD;
&#xD;
          -  Subjects with the central phalanx of the middle finger circumference &gt; 71 mm or &lt; 43&#xD;
             mm&#xD;
&#xD;
          -  Subjects with the exfoliative skin diseases (limitation due to participant discomfort)&#xD;
&#xD;
          -  Subjects with lymphoedema (limitation due to participant discomfort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregoire Wuerzner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Sola, PhD</last_name>
    <phone>+41797689800</phone>
    <email>josep@aktiia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Lausanne Hospitals</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire Wuerzner, MD</last_name>
      <phone>+41213141131</phone>
      <email>gregoire.wuerzner@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.aktiia.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

